Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in early trial

NCT ID NCT06248814

Completed Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Researchers also looked at whether the drug could reduce eczema severity and affect certain immune cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATITIS ATOPIC

Contacts and locations

Locations

  • Local Institution - 0001

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Local Institution - 0002

    Córdoba, X, 14004, Spain

  • Local Institution - 0004

    Prague, PR, 100 00, Czechia

  • Local Institution - 0005

    Chemnitz, Saxony, 09117, Germany

  • Local Institution - 0006

    Clermont-Ferrand, 63003, France

  • Local Institution - 0008

    Pierre-Bénite, 69495, France

  • Local Institution - 0009

    Pardubice, 530 02, Czechia

  • Local Institution - 0010

    Nice, 06200, France

  • Local Institution - 0011

    Berlin, State of Berlin, 10117, Germany

  • Local Institution - 0012

    Lübeck, Schleswig-Holstein, 23562, Germany

  • Local Institution - 0013

    Las Palmas de Gran Canaria, GC, 35010, Spain

  • Local Institution - 0015

    Krakow, Lesser Poland Voivodeship, 30-149, Poland

  • Local Institution - 0016

    Katowice, Silesian Voivodeship, 40-081, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.